Swiss National Bank Grows Stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Swiss National Bank increased its position in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 5.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 95,400 shares of the company's stock after buying an additional 5,200 shares during the period. Swiss National Bank owned 0.18% of PROCEPT BioRobotics worth $7,643,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Essex Investment Management Co. LLC raised its stake in shares of PROCEPT BioRobotics by 0.3% during the 3rd quarter. Essex Investment Management Co. LLC now owns 80,992 shares of the company's stock worth $6,489,000 after buying an additional 228 shares during the period. Values First Advisors Inc. purchased a new stake in PROCEPT BioRobotics in the 3rd quarter worth $27,000. Arizona State Retirement System raised its position in PROCEPT BioRobotics by 2.8% during the second quarter. Arizona State Retirement System now owns 12,840 shares of the company's stock worth $784,000 after acquiring an additional 350 shares during the period. KBC Group NV lifted its holdings in PROCEPT BioRobotics by 32.6% during the third quarter. KBC Group NV now owns 1,531 shares of the company's stock valued at $123,000 after purchasing an additional 376 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of PROCEPT BioRobotics by 4.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,913 shares of the company's stock valued at $606,000 after purchasing an additional 408 shares during the period. Institutional investors and hedge funds own 89.46% of the company's stock.

Wall Street Analyst Weigh In

PRCT has been the topic of a number of research reports. Jefferies Financial Group began coverage on shares of PROCEPT BioRobotics in a research note on Thursday, November 14th. They issued a "hold" rating and a $95.00 price target on the stock. TD Cowen upped their price objective on shares of PROCEPT BioRobotics from $75.00 to $99.00 and gave the company a "buy" rating in a research note on Monday, September 16th. Wells Fargo & Company upped their target price on PROCEPT BioRobotics from $67.00 to $69.00 and gave the company an "overweight" rating in a report on Friday, August 2nd. Bank of America raised their price target on shares of PROCEPT BioRobotics from $80.00 to $94.00 and gave the stock a "buy" rating in a report on Thursday, August 22nd. Finally, Truist Financial restated a "buy" rating and issued a $105.00 price objective (up from $95.00) on shares of PROCEPT BioRobotics in a report on Wednesday, October 30th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, PROCEPT BioRobotics presently has a consensus rating of "Moderate Buy" and an average price target of $89.50.

Insider Buying and Selling at PROCEPT BioRobotics

In other news, Director Antal Rohit Desai sold 13,305 shares of the company's stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $76.37, for a total transaction of $1,016,102.85. Following the completion of the sale, the director now owns 317,518 shares in the company, valued at $24,248,849.66. This represents a 4.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Kevin Waters sold 25,000 shares of PROCEPT BioRobotics stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $72.47, for a total transaction of $1,811,750.00. Following the completion of the sale, the chief financial officer now directly owns 96,096 shares in the company, valued at approximately $6,964,077.12. The trade was a 20.64 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 561,773 shares of company stock worth $49,073,125. 17.40% of the stock is owned by insiders.

PROCEPT BioRobotics Stock Up 1.5 %

PRCT traded up $1.49 on Tuesday, hitting $99.27. 635,181 shares of the company were exchanged, compared to its average volume of 656,847. The firm has a 50-day moving average price of $82.73 and a two-hundred day moving average price of $72.86. The company has a current ratio of 6.02, a quick ratio of 5.07 and a debt-to-equity ratio of 0.21. PROCEPT BioRobotics Co. has a twelve month low of $33.45 and a twelve month high of $103.81. The company has a market cap of $5.18 billion, a price-to-earnings ratio of -50.14 and a beta of 1.01.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last issued its earnings results on Monday, October 28th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.09. The business had revenue of $58.40 million for the quarter, compared to analyst estimates of $53.30 million. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. The business's quarterly revenue was up 66.4% on a year-over-year basis. During the same quarter last year, the company earned ($0.51) EPS. On average, equities analysts predict that PROCEPT BioRobotics Co. will post -1.74 earnings per share for the current year.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).